• LTR Pharma secures deal with pharmaceutical wholesaler Symbion for ED treatment Spontan
• Symbion will establish an Australia-wide distribution network for the nasal spray
• Partnership supports LTR Pharma’s early access scheme and lays foundation for future commercial launch

Special Report: LTR Pharma has inked a deal with leading pharmaceutical wholesaler in Australia Symbion Pty Ltd, to establish national distribution capabilities for Spontan, its novel nasal spray treatment for erectile dysfunction.

LTR Pharma (ASX:LTP) said under the deal Symbion would provide warehousing, inventory  management and nationwide distribution services for Spontan through the wholesaler’s extensive network of distribution centres servicing more than 3,900 pharmacies Australia-wide.

The non-exclusive agreement starts on March 1 and includes comprehensive quality assurance, inventory management systems and specialised handling processes tailored to pharmacy requirements.

LTR Pharma said key implementation milestones include:

• Integration of ordering and inventory management systems
• Establishment of quality control and product handling protocols
• Setup of storage facilities across Symbion’s national network
• Implementation of TGA-compliant tracking and documentation systems
• Development of pharmacist education and product support materials

Partnership supports commercial launch

LTR Pharma said the partnership provided access to established, scalable pharmaceutical infrastructure, aligning with the company’s strategy to support the early access scheme and prepare for a full-scale commercial launch post-regulatory approvals.

LTR Pharma has established early access to Spontan through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme.

Spontan is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor.

LTR Pharma said the nasal cavity was a highly vascular part of the body supporting even and rapid absorption of the drug.

Results of a pivotal trial showed a 470% faster absorption than oral vardenafil of 12 minutes versus 56 minutes.

The company emphasised its favourable safety profile positions Spontan as a disruptor in the global erectile dysfunction market.

Building partnerships for growth

LTR Pharma has been working to build up partnerships as it works towards commercialising its novel ED treatment.

The company announced in December it had partnered with specialised men’s health provider Mens Health Downunder (MHDU) to facilitate supply of Spontan.

MHDU specialises in comprehensive men’s urological healthcare solutions and currently services more than 1,000 patients annually.

In November LTR Pharma entered a strategic joint venture with the privately owned Restorative Sexual Health Clinic (RSHC) to establish a men’s health platform, which will see it capitalise on the rapidly growing telehealth market.

The JV brings together LTP’s pharmaceutical expertise and RSHC’s established clinical experience in men’s sexual health.

Launched ahead of schedule in Q4 CY24, the platform will deliver healthcare services directly to Australian men and offer a range of services.

‘Commitment to collaboration with industry leaders’

LTR Pharma executive chairman Lee Rodne said Symbion’s extensive distribution network and expertise would ensure seamless access to Spontan around Australia.

“Partnering with Symbion is a pivotal step in building our commercial infrastructure,” he said.

“This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA’s early access program, and prepare for Spontan’s anticipated commercial launch.

“Together, we are ensuring the highest standards of pharmaceutical handling and service delivery.”

This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.

 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.